125I seeds with a half-life of approximately 59.4 days were selected as the radioactive source for permanent implantation in this study, allowing approximately 95% of the needed dose to be delivered within a year [18]. Implantation of radioactive isotopes for the treatment of pancreatic carcinoma has been used for the past several decades. For example, Handly et al. reported the use of radium needle implantation in 7 patients for the treatment of pancreatic carcinoma in 1934 [19]. Of those, one patient survived up to two years. Hilaris, who was a pioneer
in the development of125I seeds for implantation for the treatment of pancreatic carcinoma, published a study of 98 patients receiving seed implants SB202190 purchase that responded with a median survival of 7 months [20], with 1 patient surviving for five years. Go6983 Pain control was achieved in 65% of patients and lasted between 5 and 47 months (with a median of 6 months). In a review study by Morrow et al., no difference in survival between patients treated with interstitial brachytherapy and patients treated by surgical resection at the same institution were observed [21]. The median survival time was 7 months, and at
least one patient survived up to five years. Pain control was achieved in 65% of the patients [22]. Syed et al. reported 18 patients treated with biliary bypass surgery,125I interstitial brachytherapy, of and EBRT [23]. Ten patients with the interstitial brachytherapy were “”sandwiched”" between two courses of EBRT. Typically, patients received 30 Gy EBRT following biopsy and bypass surgery, then 2 weeks later an additional interstitial brachytherapy of 100–150 Gy, and then an additional 15–20 Gy EBRT was administered 3–4 weeks after interstitial implantation. The results showed a 13 month median survival time in 12 patients with head and body pancreatic carcinoma.125I
seed implantation has been attempted in patients with locally advanced pancreatic carcinoma, and no difference in overall survival was found compared with the use of other techniques [24, 25]. In this study, the interstitial needle position and distribution were determined using ultrasound supervision and with the intent to spare at least 1 cm from nearby or normal tissues including the internal pancreatic duct and small blood vessels. The placement of an omental fat pad over the implanted volume was also used to protect the gastric and transverse colon mucosa from irradiation. Our results eFT-508 cell line indicate that the local control of disease was achieved in 78.6% of all patients. 87.5% (7/8) of all patients experienced complete and partial pain relief and shown satisfactory palliative effect. The overall 1-, 2- and 3-year survival rates were 33.9%, 16.9% and 7.8%, respectively with the median survival of 10 months.